Biopharma Cred. Regulatory News (BPCR)

1 November 2023

BIOPHARMA CREDIT PLC

(THE "COMPANY")

Trigger of a continuation resolution

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, announces that in accordance with Article 152(2) of the articles of association of the Company (the "Articles"), a Continuation Resolution has been triggered on account of the Company's shares having traded, on average, at a discount in excess of 10% to the Net Asset Value per Share over the 12-month rolling period ending on 31 October 2023. Pursuant to the Articles, a general meeting must be convened proposing a Continuation Resolution no later than 31 December 2023. The Company will announce further details in due course regarding the timing and agenda of the General Meeting. The Board will recommend that shareholders vote in favour of continuation.

The Company is also required to offer a further Continuation Resolution to the shareholders pursuant to Article 152(1) of the Articles at its annual general meeting in 2025.

Enquiries:

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24